Study to Examine the Effect of Antacid and Omeprazole on the Single-Dose Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects

Overview

To assess the effect of a single dose of aluminum hydroxide/magnesium hydroxide/simethicone and omeprazole on the pharmacokinetics (PK) of TBPM, following a single dose of TBPM-PI-HBr in healthy adult subjects.

Full Title of Study: “An Open-Label, 3-Period, Fixed-Sequence, Study to Examine the Effect of Aluminum Hydroxide/Magnesium Hydroxide/Simethicone and Omeprazole on the Single-Dose Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Other
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 2020

Interventions

  • Drug: Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)
    • Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) 600 mg single-dose given orally.
  • Drug: 20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL)
    • 20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL) oral suspension.
  • Drug: Omeprazole
    • 40 mg (1 x 40 mg capsule) omeprazole administered QD

Arms, Groups and Cohorts

  • Experimental: TBPM-PI-HBr Alone (Period 1)
    • Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) 600 mg single-dose given orally alone.
  • Experimental: TBPM-PI-HBr and Antacid (Period 2)
    • 20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL) oral suspension will be coadministered with 600 mg (2 x 300 mg tablets) TBPM-PI-HBr at Hour 0 on Day 1.
  • Experimental: TBPM-PI-HBr and Omeprazole (Period 3)
    • 40 mg (1 x 40 mg capsule) omeprazole administered QD at Hour -2 on Days 1 through 5, with 600 mg (2 x 300 mg tablets) TBPM-PI-HBr administered at Hour 0 on Day 5.

Clinical Trial Outcome Measures

Primary Measures

  • Area under the concentration-time curve, from time 0 to the last observed non-zero concentration (t).
    • Time Frame: Day 2 (Periods 1 and 2) and Day 6 (Period 3)
  • Area under the curve extrapolated to infinity (AUC0-∞).
    • Time Frame: Day 2 (Periods 1 and 2) and Day 6 (Period 3)
  • Percent of AUC0-inf extrapolated (AUC%extrap)
    • Time Frame: Day 2 (Periods 1 and 2) and Day 6 (Period 3)
  • Maximum plasma concentration (Cmax).
    • Time Frame: Day 2 (Periods 1 and 2) and Day 6 (Period 3)
  • Time to the maximum plasma concentration (Tmax).
    • Time Frame: Day 2 (Periods 1 and 2) and Day 6 (Period 3)
  • Terminal elimination half-life (t½).
    • Time Frame: Day 2 (Periods 1 and 2) and Day 6 (Period 3)
  • Apparent total body clearance (CL/F)
    • Time Frame: Day 2 (Periods 1 and 2) and Day 6 (Period 3)
  • Apparent volume of distribution during the terminal elimination phase after oral (extravascular) administration (Vz/F).
    • Time Frame: Day 2 (Periods 1 and 2) and Day 6 (Period 3)

Secondary Measures

  • Incidence of treatment-emergent AEs (including SAEs) categorized by severity and relationship to study drug.
    • Time Frame: 12 to 14 days after the last dose of study drug
    • ECG, Clinical Laboratories, Vitals Signs and Physical Exams will be used as a safety measure to detect any AEs.

Participating in This Clinical Trial

Key Inclusion Criteria:

  • Healthy, adult, male or female, 18-55 years of age, inclusive, at the screening visit.
  • Continuous non-smoker
  • Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m2 at the screening visit.
  • Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or ECGs, as deemed by the PI or designee.

Key Exclusion Criteria:

  • Is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected to have during the conduct of the study.
  • History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee.
  • History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study.
  • History of significant allergic disease requiring treatment
  • History or presence of alcoholism or drug abuse within the past 2 years prior to the first dose.
  • History or presence of hypersensitivity or idiosyncratic reaction to the study drugs or related compounds (especially fluoroquinolone-, carbapenem-, penicillin-, and cephalosporin-antibiotics sensitivity).
  • History of known genetic metabolism anomaly associated with carnitine deficiency (e.g., carnitine transporter defect, methylmalonic aciduria, propionic acidemia).
  • History of cholecystectomy.
  • Female subjects with a positive pregnancy test at the screening visit or first check-in or who are lactating.
  • Positive urine drug or alcohol results at the screening visit or first check-in.
  • Positive results at the screening visit for human immunodeficiency virus (HIV 1 and 2), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV).

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 55 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Spero Therapeutics
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • David Melnick, M.D., Study Director, Spero Therapeutics
  • Overall Contact(s)
    • Floni Bajraktari, +1 (857) 242-1557, fbajraktari@sperotherapeutics.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.